
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc., a clinical-stage biopharmaceutical company, reported revenue of $422K in Q2, a significant increase from $197K in Q1, indicating a strong upward trend. The company is projected to experience robust revenue growth, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026, reflecting the market's potential for its innovative therapies. Given the high unmet medical needs in cancer treatment and the company’s proprietary Trans-Arterial Micro-Perfusion therapy platform, the fundamentals suggest a positive outlook for future financial performance.
Bears say
RenovoRx Inc's financial metrics exhibit a concerning trend, with reported revenue of only $0.3 million to $0.4 million, while sustaining a significant net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08). The company's focus on developing therapies for pancreatic cancer, a disease with a dismal 5-year survival rate of 12%, raises questions regarding the potential market viability and patient impact of its treatments. Furthermore, despite growth prospects, the persistently high losses and minimal revenue generation indicate a substantial risk that could deter investment in the company's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares